

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Previously presented) An Activity Dependent Neurotrophic Factor I (ADNF I) polypeptide, the ADNF I polypeptide comprising an active core site having the following amino acid sequence:

Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:1),

wherein each amino acid of ~~the active core site~~ SEQ ID NO:1 is a D-amino acid, and wherein the ADNF I polypeptide has neurotrophic/neuroprotective activity.

2-4. (Cancelled)

5. (Currently amended) The ADNF I polypeptide of claim 1, wherein the ADNF I polypeptide consists of Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:1), wherein each amino acid is a D-amino acid.

6. (Cancelled).

7. (Withdrawn-currently amended) The ADNF I polypeptide of claim 1, wherein the ADNF I polypeptide is selected from the group consisting of:

Val-Leu-Gly-Gly-Gly- Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:14);

Val-Glu-Glu-Gly-Ile-Val-Leu-Gly-Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:15);

Leu-Gly-Gly-Gly- Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:16);

Gly-Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:17);

Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:18); and

Gly- Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:19),

wherein each amino acid of the active core site Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:1) is a D-amino acid and additional amino acids are D or L amino acids.

8. (Original) The ADNF I polypeptide of claim 1, wherein the ADNF I polypeptide comprises up to about 20 amino acids at each of an N-terminus and a C-terminus of the active core site.

9. (Original) The ADNF I polypeptide of claim 8, wherein both N-terminal and C-terminal amino acids of the ADNF I polypeptide are D-amino acids.

10-18. (Cancelled)

19. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the Activity Dependent Neurotrophic Factor I (ADNF I) polypeptide of claim 1.

20-22. (Cancelled)

23. (Currently amended) The pharmaceutical composition of claim 19, wherein the ADNF I polypeptide consists of Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:1), wherein each amino acid is a D-amino acid.

24-36. (Cancelled)

37. (Withdrawn) The pharmaceutical composition of claim 19, wherein the composition is formulated for intranasal, intraperitoneal, subcutaneous, gavage, sublingual, intravenous, or oral administration.

38. (Withdrawn) The pharmaceutical composition of claim 19, wherein the composition is formulated for oral administration.

39-41. (Cancelled)

42. (Previously presented) A method for reducing neuronal cell death, the method comprising contacting the neuronal cells with an Activity Dependent Neurotrophic Factor I (ADNF I) polypeptide of claim 1 in an amount sufficient to prevent neuronal cell death.

43. (Cancelled)

44. (Currently amended) The method of ~~claim 43~~ claim 42, wherein the ADNF I polypeptide consists of Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:1), wherein each amino acid is a D-amino acid.

45-52. (Cancelled)

53. (Original) The method of claim 42, wherein the neuronal cells are selected from the group consisting of spinal cord neurons, hippocampal neurons, cerebral cortical neurons and cholinergic neurons.

54-80. (Cancelled)